New risk model may personalize Post-Chemo decisions for nasopharyngeal cancer

This observational study is testing whether a new tool called RAIRI can better identify which patients with nasopharyngeal cancer might benefit from additional therapy after standard chemoradiation. About 900 adults with non-metastatic disease will be followed to see if the RAIRI model, which uses blood tests and MRI scans, can accurately predict outcomes and guide treatment choices. The goal is to avoid unnecessary treatments for low-risk patients while ensuring high-risk patients get the extra help they need.